Selumetinib

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Healthy Volunteers Pharmacokinetic Study

Conditions

Healthy Volunteers Pharmacokinetic Study

Trial Timeline

Oct 1, 2013 → May 1, 2014

NCT ID

NCT01960374

About Selumetinib

Selumetinib is a phase 1 stage product being developed by AstraZeneca for Healthy Volunteers Pharmacokinetic Study. The current trial status is completed. This product is registered under clinical trial identifier NCT01960374. Target conditions include Healthy Volunteers Pharmacokinetic Study.

What happened to similar drugs?

20 of 20 similar drugs in Healthy Volunteers Pharmacokinetic Study were approved

Approved (20) Terminated (1) Active (0)

✅mRNA-1273.712ModernaApproved

✅Cholestyramine + Colesevelam HClDaiichi SankyoApproved

✅Cholestyramine + Cholestyramine + TangDaiichi SankyoApproved

✅Olmesartan medoxomil + Irbesartan + ValsartanDaiichi SankyoApproved

✅Perampanel 6 MGEisaiApproved

✅eszopiclone, zolpidem, placeboSumitomo PharmaApproved

✅Listerine Experimental Mouthwash + Colgate Cavity Protection Toothpaste + Listerine Total Care ZeroJohnson & JohnsonApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03259633	Pre-clinical	Completed	—	—	NF type1 With Inoperable Plexiform Neurofibromas
NCT04924608	Phase 3	Active	Nov 19, 2021	Feb 15, 2029	Neurofibromatosis 1
NCT05101148	Phase 1	Active	Jul 21, 2021	Apr 28, 2028	Neurofibromatosis Type 1
NCT04590235	Phase 1	Active	Dec 16, 2020	Aug 31, 2026	Neurofibromatosis 1
NCT04495127	Phase 1	Completed	Aug 31, 2020	Mar 24, 2023	Neurofibromatosis Type 1
NCT03326388	Phase 1/2	Completed	Sep 26, 2019	Feb 14, 2024	Neurofibromatosis Type 1
NCT03095248	Phase 2	Terminated	May 8, 2017	May 21, 2024	Neurofibromatosis 2
NCT02063204	Phase 1	Completed	Mar 1, 2014	Jul 1, 2014	Solid Tumours
NCT01960374	Phase 1	Completed	Oct 1, 2013	May 1, 2014	Healthy Volunteers Pharmacokinetic Study
NCT01752569	Phase 1/2	Terminated	Jun 15, 2012	Dec 20, 2017	AIDS-related Kaposi's Sarcoma

Competing Products

20 competing products in Healthy Volunteers Pharmacokinetic Study

See all competitors

Product	Company	Stage	Hype Score
Use of Wearable Digital Sensors After mRNA Vaccination in Adults	Moderna	Preclinical	0
mRNA-0184	Moderna	Phase 1	0
mRNA-6231	Moderna	Phase 1	0
Letrozole	Dr. Reddy's Laboratories	Phase 1	26
Isotretinoin	Dr. Reddy's Laboratories	Phase 1	26
Fexofenadine	Dr. Reddy's Laboratories	Phase 1	26
Sertraline	Dr. Reddy's Laboratories	Phase 1	26
Nizatidine + Axid	Dr. Reddy's Laboratories	Phase 1	26
Anastrozole	Dr. Reddy's Laboratories	Phase 1	26
mRNA-1273.712	Moderna	Approved	0
Risperidone	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
Metformin + Glucophage	Dr. Reddy's Laboratories	Phase 1	26
Lamotrigine	Dr. Reddy's Laboratories	Phase 1	26
mRNA-0184	Moderna	Phase 1	0
Divalproex Sodium	Dr. Reddy's Laboratories	Phase 1	26
Sirolimus	Dr. Reddy's Laboratories	Phase 1	26
Glimepiride	Dr. Reddy's Laboratories	Phase 1	26
Ziprasidone Hydrochloride	Dr. Reddy's Laboratories	Phase 1	26
Naproxen sodium	Dr. Reddy's Laboratories	Phase 1	26